Loading organizations...

§ Private Profile · Laguna Hills, CA, USA
Vessix Vascular is a technology company.
Vessix Vascular develops a catheter-based renal denervation system for uncontrolled hypertension. Its Vessix System uses balloon-based technology with radiofrequency electrodes, delivering precise bipolar energy. This ensures efficient therapy, minimizing patient discomfort with a brief 30-second treatment per artery. It accurately targets renal nerves, eliminating the need for external cooling or grounding pads.
Founded in 2003 by Tom Steinke as Minnow Medical, Inc., the company addressed drug-resistant hypertension. Steinke envisioned a novel interventional method, creating a less invasive, highly effective device for modulating renal nerves. This provided a therapeutic option for patients unresponsive to conventional medical treatments.
Vessix Vascular serves individuals with uncontrolled hypertension needing advanced therapies. Its vision is to significantly improve patient outcomes by providing safe, efficient, and precise treatment. Focusing on targeted nerve modulation, Vessix aims to offer a durable solution that enhances quality of life and reduces cardiovascular risks.
Vessix Vascular has raised $27.7M across 2 funding rounds.
Vessix Vascular has raised $27.7M in total across 2 funding rounds.
Vessix Vascular is a medical device company that developed a balloon-based, bipolar radiofrequency (RF) renal denervation system designed to treat uncontrolled hypertension by delivering short, localized RF energy to the renal artery nerves; the company was acquired by Boston Scientific in 2012 and its Vessix System has since been integrated into Boston Scientific’s peripheral interventions portfolio and global clinical programs[4][1].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Medtech Landscape
Quick Take & Future Outlook
Quick take: Vessix developed a technically distinct, clinician‑friendly bipolar RF balloon system aimed at making renal denervation faster and more localized; its acquisition by Boston Scientific validated the approach and positioned the technology for larger‑scale clinical evaluation and commercialization under an established medtech platform[4][1].
Vessix Vascular has raised $27.7M across 2 funding rounds. Most recently, it raised $23.0M Series B in August 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2011 | $23M Series B | — | Andera Partners, Christopher Weil & Company, Dinova Capital, Fjord Invest, Neomed Management, Vince Burgess | Announced |
| Oct 20, 2010 | $4.7M Venture Round | Neomed Management | Olav Bergheim, Christopher Weil & Company | Announced |
Vessix Vascular has raised $27.7M in total across 2 funding rounds.
Vessix Vascular's investors include Andera Partners, Christopher Weil & Company, DiNovA Capital, Fjord Invest, NeoMed Management, Vince Burgess, Olav Bergheim.